Biopharma CEOs pledge commitment to safe vaccines The CEOs from nine biopharmaceutical companies have pledged to remain committed to upholding the integrity of the scientific process as they work toward global regulatory filings and approvals for COVID-19 vaccines.
Experts draw lessons from FDA's hydroxychloroquine EUA controversy Public health and regulatory experts advocated for changes to the U.S. Food and Drug Administration (FDA) emergency use authorization (EUA) process in a viewpoint published online August 31 in the Journal of the American Medical Association. They offer a set of recommendations to improve the process going forward as more COVID-19 vaccines and treatments emerge. Discuss
Detecting SARS-CoV-2 in blood may be early indicator of severe disease A blood test that measures SARS-CoV-2 RNA when patients are admitted to the hospital with COVID-19 symptoms can be a powerful diagnostic tool to predict how severe their disease will be, according to a study published in Clinical Infectious Diseases on August 28. Patients without viral RNA in their blood have a good chance at rapid recovery, concluded researchers from Karolinska Institutet and Danderyd Hospital. Discuss
Cartesian begins trial of RNA-based cell therapy for COVID-19 Cartesian Therapeutics has initiated a phase I/II clinical trial for the use of its Descartes-30 lead RNA-engineered mesenchymal stem cell therapy in patients with moderate-to-severe acute respiratory distress syndrome (ARDS), including ARDS caused by COVID-19.